Aims and Scope

Nowadays, cancer has gradually become the leading cause of death worldwide and seriously endangering the health and life of humans for a long period. It has been reported that cancer can be caused by one of the three ways namely, incorrect diet, genetic predisposition and environmental contaminants. Consistent efforts have been made to fight against this disease in the past few years as a result of advancements in cellular and molecular biology leading to the development of potent anticancer agents capable of targeting the cancerous tissues with minimal side effects. Natural products have appreciably contributed to the development of a large number of anticancer drugs. About 50% of all anticancer drugs approved internationally are either natural products or natural product mimics and were developed on the basis of the knowledge obtained from small or macromolecules existing in nature. Recently, various azole derivatives have attracted considerable attention in the field of anticancer research. Among them, derivatives are an important class of five membered nitrogen-oxygen containing heterocyclic compounds that exhibited promising anti-neoplastic properties. Viewing the importance of natural products as well as azole containing pharmacores in the field of cancer research, the present thematic issue is mainly focused on those natural products which bear azole moiety exhibiting anticancer potential. Furthermore, articles covers various pathways, influence of stereo-chemical aspects and structure activity relationship studies particularly related to anticancer activity of such compounds are most welcome.

Keywords
Anti-neoplastic agents, azoles, cancer therapy, mode of action, natural products, signaling pathways

Subtopics:
Azoles containing natural products in management of cancer.
Iron regulation in cancer research: promises and challenges.
Azole based nucleoside analogues as potential antitumour agents.
Design, Synthesis and evaluation of some azole based heterocycles as anticancer agents.
Iron chelation and drug resistance in cancer.
Schedule:

Manuscript submission deadline: December 2018.
Peer Review Due: January 2019.
Revision Due: February 2019.
Notification of acceptance by the Guest Editor: March 2019.
Final manuscripts due: April 2019.